Intranasal Single-Replication Influenza Vector Induces Cross-Reactive Serum and Mucosal Antibodies against SARS-CoV-2 Variants

Current SARS-CoV-2 vaccines provide protection for COVID-19-associated hospitalization and death, but remain inefficient at inhibiting initial infection and transmission. Despite updated booster formulations, breakthrough infections and reinfections from emerging SARS-CoV-2 variants are common. Intr...

Descripción completa

Detalles Bibliográficos
Autores principales: Moser, Michael J., Hill-Batorski, Lindsay, Bowen, Richard A., Matejka, Sarah M., Marshall, David, Kawaoka, Yoshihiro, Neumann, Gabriele, Bilsel, Pamuk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302585/
https://www.ncbi.nlm.nih.gov/pubmed/37376452
http://dx.doi.org/10.3390/vaccines11061063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302585/
https://www.ncbi.nlm.nih.gov/pubmed/37376452
http://dx.doi.org/10.3390/vaccines11061063

Ejemplares similares